Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation

Junjie Li, Xiaochao Qu, Jie Tian, Jian-Ting Zhang, Ji Xin Cheng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Recent advances have recognized metabolic reprogramming as an underlying mechanism for cancer drug resistance. However, the role of cholesterol metabolism in drug resistance remain elusive. Herein, we report an increased accumulation of cholesteryl ester in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) cells. A potent inhibitor of acyl-CoA cholesterol acyltransferase-1 (ACAT-1), avasimibe, effectively suppressed proliferation of gemcitabine-resistant PDAC cells. Combination of avasimibe and gemcitabine showed strong synergistic effect in suppressing PDAC cell viability in vitro and tumor growth in vivo. Immunoblotting analysis suggests downregulation of Akt by avasimibe is likely to contribute to the synergism. Collectively, our study demonstrates a new combinational therapeutic strategy to overcome gemcitabine resistance for PDAC treatment.

Original languageEnglish (US)
Article numbere0193318
JournalPLoS One
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

gemcitabine
Esterification
esterification
adenocarcinoma
Adenocarcinoma
Cholesterol
cholesterol
drug resistance
Drug Resistance
cholesterol acyltransferase
cholesterol metabolism
neoplasms
cholesteryl esters
Cholesterol Esters
synergism
immunoblotting
Immunoblotting
Metabolism
Pharmaceutical Preparations
cell viability

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation. / Li, Junjie; Qu, Xiaochao; Tian, Jie; Zhang, Jian-Ting; Cheng, Ji Xin.

In: PLoS One, Vol. 13, No. 2, e0193318, 01.02.2018.

Research output: Contribution to journalArticle

Li, Junjie ; Qu, Xiaochao ; Tian, Jie ; Zhang, Jian-Ting ; Cheng, Ji Xin. / Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation. In: PLoS One. 2018 ; Vol. 13, No. 2.
@article{ccd32306abef43b898901daaf47c994a,
title = "Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation",
abstract = "Recent advances have recognized metabolic reprogramming as an underlying mechanism for cancer drug resistance. However, the role of cholesterol metabolism in drug resistance remain elusive. Herein, we report an increased accumulation of cholesteryl ester in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) cells. A potent inhibitor of acyl-CoA cholesterol acyltransferase-1 (ACAT-1), avasimibe, effectively suppressed proliferation of gemcitabine-resistant PDAC cells. Combination of avasimibe and gemcitabine showed strong synergistic effect in suppressing PDAC cell viability in vitro and tumor growth in vivo. Immunoblotting analysis suggests downregulation of Akt by avasimibe is likely to contribute to the synergism. Collectively, our study demonstrates a new combinational therapeutic strategy to overcome gemcitabine resistance for PDAC treatment.",
author = "Junjie Li and Xiaochao Qu and Jie Tian and Jian-Ting Zhang and Cheng, {Ji Xin}",
year = "2018",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0193318",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation

AU - Li, Junjie

AU - Qu, Xiaochao

AU - Tian, Jie

AU - Zhang, Jian-Ting

AU - Cheng, Ji Xin

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Recent advances have recognized metabolic reprogramming as an underlying mechanism for cancer drug resistance. However, the role of cholesterol metabolism in drug resistance remain elusive. Herein, we report an increased accumulation of cholesteryl ester in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) cells. A potent inhibitor of acyl-CoA cholesterol acyltransferase-1 (ACAT-1), avasimibe, effectively suppressed proliferation of gemcitabine-resistant PDAC cells. Combination of avasimibe and gemcitabine showed strong synergistic effect in suppressing PDAC cell viability in vitro and tumor growth in vivo. Immunoblotting analysis suggests downregulation of Akt by avasimibe is likely to contribute to the synergism. Collectively, our study demonstrates a new combinational therapeutic strategy to overcome gemcitabine resistance for PDAC treatment.

AB - Recent advances have recognized metabolic reprogramming as an underlying mechanism for cancer drug resistance. However, the role of cholesterol metabolism in drug resistance remain elusive. Herein, we report an increased accumulation of cholesteryl ester in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) cells. A potent inhibitor of acyl-CoA cholesterol acyltransferase-1 (ACAT-1), avasimibe, effectively suppressed proliferation of gemcitabine-resistant PDAC cells. Combination of avasimibe and gemcitabine showed strong synergistic effect in suppressing PDAC cell viability in vitro and tumor growth in vivo. Immunoblotting analysis suggests downregulation of Akt by avasimibe is likely to contribute to the synergism. Collectively, our study demonstrates a new combinational therapeutic strategy to overcome gemcitabine resistance for PDAC treatment.

UR - http://www.scopus.com/inward/record.url?scp=85042688677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042688677&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0193318

DO - 10.1371/journal.pone.0193318

M3 - Article

C2 - 29489864

AN - SCOPUS:85042688677

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0193318

ER -